摘要
目的探讨肿瘤四项联合C反应蛋白(CRP)在乳腺癌诊断中的应用价值。方法选取2019年4月至2021年6月本院收治的150例乳腺癌患者作为研究组,另选取同期150名健康体检者作为对照组,比较两组血清癌胚抗原(CEA)、糖链抗原153(CA153)、细胞角蛋白片段21-1(CYFRA21-1)、组织多肽特异性抗原(TPS)及C反应蛋白(CRP)水平及各项指标单独检测和联合检测的阳性率。结果研究组CEA、CA153、CYFRA21-1、TPS及CRP水平均明显高于对照组,差异有统计学意义(P<0.05);研究组CEA、CA153、CYFRA21-1、TPS及CRP单独或联合检测的阳性率均高予对照组,差异有统计学意义(P<0.05);研究组中单项检测的阳性率从高到低依次为:CA153(36.66%)、CEA(30.66%)、TPS(30.00%)、CRP(28.00%)、CYFRA21-1(26.66%),肿瘤四项联合CRP的阳性率可达62.00%,差异有统计学意义(P<0.05)。结论肿瘤四项联合CRP能有效提高乳腺癌检出率,肿瘤四项检测指标联合CRP是检查乳腺癌较为适宜的搭配,值得临床推广应用。
Objective To explore the value of four tumor items combined with C-reactive protein(CRP)in the diagnosis of breast cancer.Methods 150 patients with breast cancer admitted to our hospital from April 2019 to June 2021 were selected as the study group,and 150 health examinees in the same period were selected as the control group.The positive rates of serum carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),cytokeratin fragment 21-1(CYFRA21-1),tissue polypeptide-specific(TPS)and C-reactive protein(CRP)levels and various indicators were compared between the two groups.Results The levels of CEA,CA153,CYFRA21-1,TPS and CRP in the study group were significantly higher than those in the control group,the differences were statistically significant(P<0.05).The positive rates of CEA,CA153,CYFRA21-1,TPS,and CRP alone or in combination in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).The positive rates of individual tests in the study group ranged from high to low,including CA153(36.66%),CEA(30.66%),TPS(30.00%),CRP(28.00%),and CYFRA21-1(26.66%);the positive rate of the combination of the four tumor markers with CRP reached 62.00%,the difference was statistically significant(P<0.05).Conclusion The combination of four tumor detection indicators and CRP can effectively improve the detection rate of breast cancer,the combination of four tumor detection indicators and CRP is a more appropriate combination for the detection of breast cancer,which is worthy of clinical promotion and application.
作者
夏甜甜
冯瑶
赵清辉
XIA Tiantian;FENG Yao;ZHAO Qinghui(Department of Oncology,the Third People's Hospital of Jingdezhen,Jingdezhen,Jiangxi,333000,China)
出处
《当代医学》
2023年第23期144-146,共3页
Contemporary Medicine
